Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

30 March 2022: Clinical Research

Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse

Liyang Zhou 1ABCDEF* , Qin He 1CEF* , Xitao Liu 2DEF* , Xiaoan Yang 3BC , Xueting Ou 1EF , Bing Situ 2DF , Yueping Li 4DE , Xingfei Pan 1DEFG* , Qihuan Xu 3AE*

DOI: 10.12659/MSM.934785

Med Sci Monit 2022; 28:e934785

Table 1 Demographic information and clinical characteristics of the enrolled patients.

FactorsBefore PEG-IFN-α regimenAfter PEG-IFNα regimen
Gender, M/F91/1791/17
Age, year28±8
Total treatment duration, month48 (48, 69)
Total follow-up period, week245 (16, 360)
ALT, U/L173 (84, 294)40 (28, 66)
AST, U/L103 (60, 156)36 (27, 52)
Quantitative value of HBsAg, COI5860 (2828, 7232)2120 (17, 6874)
HBV DNA, log10 copies/ml6.8 (5.8, 7.5)2 (2, 2)
Rate of HBeAg seroconversion, %75.00 (81/108)
Rate of HBsAg seroconversion, %17.59 (19/108)
ALT normalization rate, %60.19 (65/108)
Peg-IFNα – pegylated interferon alfa; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HBeAg – Hepatitis B e antigen; ALT – alanine aminotransferase; AST – aspartate aminotransferase.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750